CSL Limited: all 268 studies

Page 2 of 3. Open to participants first (19), then studies with results posted, then the rest; newest registration first within each.

• A Phase 3 Study to Investigate the Safety and Efficacy of PA21, a Phosphate Binder, in Dialysis PatientsCompletedNCT01324128Phase 3Results posted
• Study of Subcutaneous Immune Globulin in Patients Requiring IgG Replacement Therapy (Japan Study)CompletedNCT01199705Phase 3Results posted
• Study of Efficacy and Safety of Privigen in Subjects With Chronic Inflammatory Demyelinating PolyneuropathyCompletedNCT01184846Phase 3Results posted
• Evaluation of Patiromer Titration in Heart Failure Patients With Chronic Kidney DiseaseCompletedNCT01130597Phase 2Results posted
• A Clinical Trial of CSL's 2010/2011 Formulation of Enzira® in a Healthy Adult PopulationCompletedNCT01113580Phase 4Results posted
• Ferric Carboxymaltose (FCM) Assessment in Subjects With Iron Deficiency Anaemia and Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD)CompletedNCT00994318Phase 3Results posted
• A Study to Determine the Immunogenicity and Safety Profile of CSL Limited's Influenza Virus Vaccine Compared to a US Licensed Comparator Influenza Virus Vaccine in a Pediatric PopulationCompletedNCT00959049Phase 3Results posted
• A Clinical Trial of CSL's 2009 H1N1 Influenza Vaccine (CSL425) in a Healthy Pediatric Population in the USACompletedNCT00958243Phase 2Results posted
• A Clinical Trial of CSL's 2009 H1N1 Influenza Vaccine (CSL425) in Healthy Adults in the USACompletedNCT00958126Phase 2Results posted
• An Open Enrollment Study of Factor XIII Concentrate in Subjects With Congenital Factor XIII DeficiencyCompletedNCT00945906Phase 3Results posted
• A Clinical Trial of CSL's 2009 H1N1 Influenza Vaccine (CSL425) in Healthy ChildrenCompletedNCT00940108Phase 2Results posted
• A Clinical Trial of CSL's 2009 H1N1 Influenza Vaccine (CSL425) in Healthy AdultsCompletedNCT00938639Phase 2Results posted
• A Study to Assess the Immunogenicity and Safety of CSL's 2009 / 2010 Formulation of Enzira® Vaccine in Healthy VolunteersCompletedNCT00888381Phase 4Results posted
• A Study of Factor XIII Concentrate in Subjects With Congenital Factor XIII DeficiencyCompletedNCT00885742Phase 3Results posted
• A Study of the Use of Factor XIII Concentrate in Patients With Inherited FXIII DeficiencyCompletedNCT00883090Phase 2Results posted
• Evaluation of Patiromer in Heart Failure PatientsCompletedNCT00868439Phase 2Results posted
• Safety Study of CSL Limited's Influenza Virus Vaccine in the Paediatric Population Aged >= 6 Months to < 18 YearsCompletedNCT00825162Phase 4Results posted
• Study of Phosphate Levels in Patients With Chronic Kidney DiseaseCompletedNCT00824460Phase 2Results posted
• An Open-label, Randomized, Multicenter Phase IIIb Study to Assess the Efficacy, Safety and Tolerance of BERIPLEX® P/N (Kcentra) Compared With Plasma for Rapid Reversal of Coagulopathy Induced by Vitamin K Antagonists in Subjects Requiring an Urgent Surgical ProcedureCompletedNCT00803101Phase 3Results posted
• Study of Subcutaneous Immune Globulin in Patients Requiring IgG Replacement Therapy (EU Extension Study)CompletedNCT00751621Phase 3Results posted
• A Study to Determine the Immunogenicity and Safety Profile of CSL Limited's Influenza Virus Vaccine Compared to a US Licensed Comparator Influenza Virus VaccineCompletedNCT00735475Phase 4Results posted
• Extension Study of Subcutaneous Immunoglobulin Human in Patients With Primary Immunodeficiency (PID)CompletedNCT00719680Phase 3Results posted
• Efficacy and Safety Study of BERIPLEX® P/N (Kcentra) Compared With Plasma in Patients With Acute Major Bleeding Caused by Anticoagulant TherapyCompletedNCT00708435Phase 3Results posted
• A Study of Purified Human Antibodies Administered Subcutaneously to Patients With Multifocal Motor Neuropathy (MMN)CompletedNCT00701662Phase 2Results posted
• Extension Study of Zemaira® i.v. Administration in Subjects With Emphysema Due to alpha1-proteinase Inhibitor Deficiency.CompletedNCT00670007Phase 4Results posted
• A Study of the Efficacy, Safety and Tolerability Profile of CSL Limited's Influenza Virus Vaccine (CSL's IVV) Administered Intramuscularly in Healthy AdultsCompletedNCT00562484Phase 4Results posted
• Study of Subcutaneous Immune Globulin in Patients Requiring IgG Replacement TherapyCompletedNCT00542997Phase 3Results posted
• Efficacy and Safety of Vivaglobin® in Previously Untreated Patients With Primary ImmunodeficiencyCompletedNCT00520494Phase 4Results posted
• Human Fibrinogen - PharmacokineticsCompletedNCT00496262Phase 2Results posted
• Study of Subcutaneous Immunoglobulin in Patients With PID Requiring IgG Replacement TherapyCompletedNCT00419341Phase 3Results posted
• Safety and Efficacy of Intravenous Immunoglobulin IgPro10 in Patients With Primary Immunodeficiencies (PID)CompletedNCT00322556Phase 3Results posted
• C1 Esterase Inhibitor in Hereditary Angioedema (HAE)(Extension Study)CompletedNCT00292981Phase 3Results posted
• Zemaira in Subjects With Emphysema Due to Alpha1-Proteinase Inhibitor DeficiencyCompletedNCT00261833Phase 4Results posted
• Human C1 Esterase Inhibitor (C1-INH) in Subjects With Acute Abdominal or Facial Hereditary Angioedema (HAE) AttacksCompletedNCT00168103Phase 2/3Results posted
• Treatment of Chronic Immune Thrombocytopenic Purpura (ITP) With Intravenous Immunoglobulin IgPro10CompletedNCT00168038Phase 3Results posted
• Efficacy and Safety of Vamifeport in Adult Participants With Homeostatic Iron Regulator Gene (HFE)-Related Hereditary HemochromatosisActive, not recruitingNCT07332091Phase 2
• An Open-label, Multicenter Study to Assess the Pharmacokinetics (PK), Safety, and Tolerability of Subcutaneous IgPro20 in Immunoglobulin (IG) Treatment-naïve Participants With Primary Immunodeficiency (PID)CompletedNCT07076446Phase 4
• Effect of Food on the Oral Bioavailability of a Prolonged-release Formulation of Vamifeport in Healthy AdultsCompletedNCT06996184Phase 1
• Safety Study in Subjects ≥ 12 Years of Age With Hereditary Angioedema Switching to GaradacimabCompletedNCT06806657Phase 4
• Recombinant Single-chain Factor VIII (rVIII-SingleChain) in Chinese Participants With Hemophilia A Previously Treated With FVIII ProductsCompletedNCT06738485Phase 3
• Pharmacokinetics and Pharmacodynamics of Two Prolonged-release Formulations of Vamifeport in Healthy AdultsCompletedNCT06726863Phase 1
• Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Chinese Subjects With Hemophilia B Previously Treated With FIX TherapyCompletedNCT06399289Phase 3
• A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults ≥65 Years of AgeCompletedNCT06087640Phase 3
• Safety, Reactogenicity, and Immunogenicity Study of a Self-Amplifying MRNA Influenza Vaccine in Healthy AdultsCompletedNCT06028347Phase 1
• The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and OlderCompletedNCT06015282Phase 3
• First-In-Human Study To Evaluate The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Escalating Single And Multiple Doses Of CSL040 In Healthy SubjectsCompletedNCT05937581Phase 1
• Avacostar - (PASS)Active, not recruitingNCT05897684
• Study to Evaluate Immunogenicity, Safety and Tolerability of Adjuvanted and Non-Adjuvanted H2N3 Influenza Vaccines in AdultsCompletedNCT05875961Phase 1
• Study to Evaluate Safety and Immunogenicity of Different Priming and Booster Regimens With Adjuvanted H5N8 and/or H5N6 Influenza Vaccine in AdultsCompletedNCT05874713Phase 2
• FDDA Utilization Study (FDDAU)TerminatedNCT05861492Not applicable
• Effects of CSL324 in the Lung After Segmental ChallengeCompletedNCT05653713Phase 1
• Cross-sectional Study to Assess Prevalence and Burden of CKD-associated Pruritus in Hemodialysis PatientsWithdrawnNCT05625542
• Cross-sectional Study to Assess Prevalence and Burden of CKD-associated Pruritus in Haemodialysis PatientsCompletedNCT05524467
• Study of the Prevalence of Iron Deficiency in Elderly Patient in Hospital EnvironmentCompletedNCT05514951Not applicable
• RAYALDEE Non Interventional Study (NIS) on Effectiveness in ND-CKD SHPT PatientsCompletedNCT05460234
• Assess Burden of Disease Among Kidney Transplant Recipients With Chronic Active Antibody Mediated RejectionCompletedNCT05452317
• Study of AAV5-hFIX in Severe or Moderately Severe Haemophilia BCompletedNCT05360706
• A Study to Compare the Pharmacokinetics of CSL312 Administered by Prefilled Syringe Assembled to Autoinjector to the Pharmacokinetics Administered by Prefilled Syringe Assembled to Needle Safety Device in Healthy SubjectsCompletedNCT05306275Phase 1
• Trial Evaluating the Efficacy and Safety of Patiromer in Chinese SubjectsCompletedNCT05136664Phase 3
• Observatory of Patients With Haemophilia B Treated by IdElvion®Active, not recruitingNCT05086575
• Bioavailability Study Comparing 2 Vamifeport Oral Formulations in Fasted Versus Fed State in Healthy SubjectsCompletedNCT05077436Phase 1
• Efficacy and Safety Study of Multiple Doses of VIT-2763 in Adults With Transfusion-dependent Beta-thalassemiaWithdrawnNCT04938635Phase 2
• Cardiovascular and Renal Treatment in Heart Failure Patients With Hyperkalaemia or at High Risk of HyperkalaemiaCompletedNCT04864795
• An Efficacy, Immunogenicity and Safety Study Investigating an Adjuvanted SARS-CoV-2 Influenza Vaccine to Protect Against COVID-19 in Adults Over Aged 18 Years-old and OlderWithdrawnNCT04806529Phase 2/3
• Study of the Prevalence of Iron Deficiency in Patients With Scheduled Major Surgery (CARENFER PBM)Status unknownNCT04800042Not applicable
• Register of Patients With haEmophilia A tReated With Afstyla®CompletedNCT04675541
• Registry of Patients With Von WilLEbrand Disease Treated With Voncento®CompletedNCT04657887
• Study to Assess CSL787 in Non-cystic Fibrosis Bronchiectasis (NCFB)CompletedNCT04643587Phase 1
• Pharmacokinetics, Safety, and Tolerability of CSL760, an Intravenous Anti-SARS-CoV-2 Hyperimmune Globulin, in Healthy Adult SubjectsTerminatedNCT04638634Phase 1
• A Study to Assess the Pharmacokinetics and Safety of CSL312 in Healthy Japanese and Caucasian AdultsCompletedNCT04580654Phase 1
• Pharmacokinetics and Safety of Subcutaneous CSL324 in Healthy Japanese and White SubjectsCompletedNCT04570267Phase 1
• CSL324 in COVID-19WithdrawnNCT04519424Phase 2
• Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneous CSL730 in Healthy Adult SubjectsTerminatedNCT04446000Phase 1
• Safety of Single Doses of CSL889 in Adult Patients With Sickle Cell DiseaseCompletedNCT04285827Phase 1
• A Clinical Study to Test the Efficacy and Safety of CSL312 on Catheter-associated Blood Clot Formation in Subjects With Cancer Who Receive Chemotherapy Through a PICC LineWithdrawnNCT04281524Phase 1/2
• Respreeza® Self-administration and Learning Program (AmAREtTI Study)CompletedNCT04262284
• Efficacy and Safety of IgPro10 in Adults With Systemic Sclerosis (SSc)WithdrawnNCT04138485Phase 2
• Study of the Prevalence of Iron Deficiency in Patients With Chronic Inflammatory Bowel DiseaseStatus unknownNCT04123990Not applicable
• Study of the Prevalence of Iron Deficiency in Patients With Chronic Renal Failure But Non-Dialysis (CARENFER IRC-ND)Status unknownNCT04123145Not applicable
• CSL200 Gene Therapy in Adults With Severe Sickle Cell DiseaseTerminatedNCT04091737Phase 1
• A Clinical Study to Test the Safety, Exposure, and Pharmacodynamic Markers of CSL311 in Patients With Mild-to-moderate Asthma and in Healthy VolunteersCompletedNCT04082754Phase 1
• Safety and Pharmacokinetics of Repeat Doses of CSL324 in Subjects With Hidradenitis Suppurativa and Palmoplantar PustulosisCompletedNCT03972280Phase 1
• Prevalence Study of Iron Deficiency in Patients With CancerStatus unknownNCT03924271Not applicable
• Study of the Prevalence of Iron Deficiency in Patients With Heart FailureStatus unknownNCT03924258Not applicable
• Comparative Effectiveness of AKYNZEO® and Standard of Care (Including EMEND®) for the Prevention of Nausea and Vomiting (CINV) in Cancer PatientsStatus unknownNCT03831633Phase 4
• The Safety and Efficacy of Alpha-1 Antitrypsin (AAT) for the Prevention of Graft-versus-host Disease (GVHD) in Patients Receiving Hematopoietic Cell TransplantTerminatedNCT03805789Phase 2/3
• Evaluating the Effectiveness of Telemonitoring System in the Management of Patients With CIDPTerminatedNCT03779828
• PA21 Safety and Efficacy in Adult Chinese SubjectsCompletedNCT03644264Phase 3
• Afluria Pregnancy RegistryCompletedNCT03442582
• Flucelvax (TIVc or QIVc) Pregnancy RegistryCompletedNCT03438487
• Assessing the Safety and Tolerability of CSL730 in Healthy Caucasian and Japanese AdultsTerminatedNCT03375606Phase 1
• Artificial Intelligence for Optimal Anemia Management in End-stage Renal Disease: The Anemia Control Model (ACM) TrialTerminatedNCT03214627Not applicable
• Broncho-Vaxom (OM 85 BV) in Children Suffering From Atopic DermatitisCompletedNCT03047954Phase 3
• Study of Immune Deficiency Patients Treated With Subcutaneous Immunoglobulin (IgPro20, Hizentra®) on Weekly and Biweekly SchedulesCompletedNCT02711228Phase 4
• Non-interventional Study to Investigate the Short and Long Term Real-life Safety, Effectiveness, and Adherence of Velphoro® in Patients With Hyperphosphataemia Undergoing Haemodialysis (HD) or Peritoneal Dialysis (PD)CompletedNCT02687594
• Study of Voncento® in Subjects With Von Willebrand DiseaseCompletedNCT02552576Phase 4
• Study of Recombinant Factor VIIa Fusion Protein (rVIIa-FP, CSL689) for On-demand Treatment of Bleeding Episodes in Patients With Hemophilia A or B With InhibitorsTerminatedNCT02484638Phase 2/3
• Study of the Pharmacokinetics and Safety of Recombinant Factor VIIa Fusion Protein (rVIIa-FP, CSL689) in Patients With Congenital Factor VII DeficiencyCompletedNCT02470871Phase 1
• An Observational Cohort Study of the Safety and Efficacy of Fibrinogen Concentrate, Human (FCH) in Subjects With Congenital Fibrinogen DeficiencyCompletedNCT02427217
• A Study of CSL112 in Healthy Adults and in Adults With Moderate Renal ImpairmentCompletedNCT02427035Phase 1

← CSL Limited overview and focus areas